The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract

The HER-2/neu oncogene is localized to chromosome 17q and shares significant homology with the epidermal growth factor receptor. As a result of its potential role in the selection of therapy, HER-2/neu testing has reached near-standard-ofpractice status in breast cancer. There is considerable interest in HER-2/neu as a prognostic factor and target of therapy in tumors of the gastrointestinal tract. In this review of HER-2/neu expression in esophageal squamous cell carcinoma and adenocarcinomas of the esophagus, stomach, and colon, a wide range of expression of HER-2/neu from 0 to 83% likely reflects both differences in methods and reagents, as well as study bias associated with patient selection (i.e., early versus advanced disease). For esophageal squamous cell carcinoma, little information exists as to the prognostic significance of HER-2/neu expression. In adenocarcinoma associated with Barrett's esophagus there is contradictory data. However, most of the information available indicates that this marker has significant prognostic value. In gastric adenocarcinoma, the wide expression range may truly reflect patient selection because HER-2/neu positivity appears linked to advanced rather than early disease with limited invasion. The majority of studies favor a significant prognostic value of HER-2/neu status for this tumor. Finally, in colorectal cancer HER-2/neu overexpression also appears to be a significant adverse outcome indicator as judged by the current published literature. In conclusion, given that either HER-2/neu protein overexpression or gene amplification is associated with approximately one-fourth of all gastrointestinal tract malignancies, strategies designed to employ the marker in therapy selection appear warranted. During the next several years it will not be surprising to see these tumors treated with antiHER-2/neu modalities such as HerceptinTM, likely in combination with other agents initially for patients with advanced disease, and possibly for individuals with high-risk lesions in an adjuvant setting.

[1]  H. Burstein,et al.  HER2 overexpressing metastatic breast cancer , 2002, Current Treatment Options in Oncology.

[2]  M. Fey.  [Adjuvant therapy for colon cancer]. , 2000, Schweizerische medizinische Wochenschrift.

[3]  H. Höfler,et al.  HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. , 2000, Human pathology.

[4]  K. Offit.  Genetic prognostic markers for colorectal cancer. , 2000, The New England journal of medicine.

[5]  J. Ross,et al.  Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. , 1999, American journal of clinical pathology.

[6]  C. Hudis,et al.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.

[7]  J. Fletcher,et al.  HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.

[8]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Ward,et al.  Clinicopathological significance of erbB-2 expression in colorectal carcinoma. , 1999, Oncology reports.

[10]  H. McLeod,et al.  Tumour markers of prognosis in colorectal cancer , 1999, British Journal of Cancer.

[11]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[12]  S. Kitano,et al.  Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival , 1998, Oncology.

[13]  K. Lam,et al.  C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  J. Fletcher,et al.  Multivariate analysis of prognostic factors in lymph node negative breast cancer , 1998 .

[15]  J. Ross,et al.  Prognostic factors in gastric cancer. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  H. Friess,et al.  Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. , 1998, Human pathology.

[17]  C. Ratto,et al.  Prognostic factors in colorectal cancer , 1998, Diseases of the colon and rectum.

[18]  H. Ikeda,et al.  A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. , 1998, Cancer research.

[19]  C. Rose,et al.  Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2. , 1998, Anticancer research.

[20]  H. Appelman,et al.  A “rose is a rose is a rose is a rose,” but exactly what is a gastric adenocarcinoma? , 1998, Journal of surgical oncology.

[21]  M. Mínguez,et al.  Barrett's esophagus, markers to distinguish risk groups. , 1998, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[22]  J. Winstanley,et al.  Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens , 1998, International Journal of Cancer.

[23]  A. Roquancourt,et al.  Variability of immunohistochemical reactivity on stored paraffin slides. , 1998, Journal of clinical pathology.

[24]  P. Terrier,et al.  Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. , 1998, European journal of cancer.

[25]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[26]  R. Fisher,et al.  Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. , 1998, Oncology research.

[27]  I. Ninomiya,et al.  Prognostic significance of c-erbB-2 gene expression in the poorly differentiated type of adenocarcinoma of the stomach. , 1998, Cancer detection and prevention.

[28]  M. Stolte,et al.  Differences in the diagnostic criteria used by japanese and western pathologists to diagnose colorectal carcinoma , 1998, Cancer.

[29]  A. Cnaan,et al.  erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. , 1997, American journal of clinical pathology.

[30]  I Vergote,et al.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. , 1997, Journal of clinical pathology.

[31]  M. Mai,et al.  Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. , 1997, The American journal of pathology.

[32]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Persons Dl,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .

[34]  A. Gelb,et al.  Prognostic Factors in Colorectal Carcinoma , 1997 .

[35]  C. Sheehan,et al.  HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. , 1997, Human pathology.

[36]  M. Stolte,et al.  Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists , 1997, The Lancet.

[37]  J. Pestano,et al.  Quantitative analysis of p185HER‐2/neu protein in breast cancer and its association with other prognostic factors , 1997, International journal of cancer.

[38]  Y. Maehara,et al.  c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. , 1997, Hepato-gastroenterology.

[39]  B. Markovic,et al.  Overexpression of c-erbB-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer. , 1997, Anticancer research.

[40]  H. P. Wang,et al.  Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. , 1997, Hepato-gastroenterology.

[41]  R. Hardwick,et al.  Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[42]  D. Persons,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[43]  K. Mafune,et al.  Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. , 1997, Cancer research.

[44]  M. Hung,et al.  Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  M. Caruso,et al.  Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. , 1996, Anticancer research.

[46]  S. Schnitt,et al.  Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. , 1996, Journal of the National Cancer Institute.

[47]  A. Tannapfel,et al.  Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation. , 1996, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[48]  Jin-Hyuk Choi,et al.  Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. , 1996, Oncology.

[49]  A. Norman,et al.  The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. , 1996, European journal of cancer.

[50]  S. Takashima,et al.  Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. , 1995, Japanese journal of clinical oncology.

[51]  S. Tatebe,et al.  Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. , 1995, Anticancer research.

[52]  J. Nesland,et al.  Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. , 1995, Anticancer research.

[53]  J. Fisher,et al.  Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Norman,et al.  The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer , 1995 .

[55]  A. Lazaris,et al.  Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. , 1995, Histology and histopathology.

[56]  F. Duhaylongsod,et al.  The Significance of c-erb B‐2 and p53 Immunoreactivity in Patients with Adenocarcinoma of the Esophagus , 1995, Annals of surgery.

[57]  R. Lupu,et al.  Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. , 1995, Seminars in cancer biology.

[58]  X. Sun,et al.  Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. , 1995, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[59]  S. Hirohashi,et al.  Comparison of the molecular genetics of c‐erb‐B2 and p53 expression in stomach cancer in Britain and Japan , 1995, Cancer.

[60]  N. Altorki,et al.  Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[61]  N. Shepherd,et al.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. , 1995, Journal of clinical pathology.

[62]  C. Potter.  The neu-oncogene: More than a prognostic indicator? , 1994 .

[63]  M. Leader,et al.  Cytoplasmic c‐erbB‐2 protein expression correlates with survival in Dukes' B colorectal carcinoma , 1994, Histopathology.

[64]  J. Chi,et al.  The prognostic significance of c-erbB-2 and p53 protein expressions in gastric carcinoma--a multivariate analysis of prognostic factors. , 1994, Journal of Korean medical science.

[65]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[66]  D. Birnbaum,et al.  Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation , 1994, The Journal of pathology.

[67]  K. Becker,et al.  Prognostic value of DNA ploidy and cerbB‐2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus , 1994, Cancer.

[68]  W. Strodel,et al.  Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. , 1994, Archives of pathology & laboratory medicine.

[69]  F. Ho,et al.  Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. , 1994, Journal of clinical pathology.

[70]  F. Paraf,et al.  Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. , 1994, Journal of clinical pathology.

[71]  I. Busmanis,et al.  Analysis Of Cerbb2 Expression Using A Panel Of 6 Commercially Available Antibodies , 1994, Pathology.

[72]  C. De Potter.  The neu-oncogene: more than a prognostic indicator? , 1994, Human pathology.

[73]  K. Pavelić,et al.  High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. , 1994, Cancer Detection and Prevention.

[74]  E. Sauter,et al.  HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. , 1993, Cancer letters.

[75]  N. Yamanaka,et al.  Relationship of C‐erbB‐2 protein expression and gene amplification to invasion and metastasis in human gastric cancer , 1993, Cancer.

[76]  H. Sasano,et al.  Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. , 1993, Human pathology.

[77]  D. Beer,et al.  Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.

[78]  S. Hirohashi,et al.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. , 1993, Cancer.

[79]  J. Jankowski,et al.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. , 1992, Gut.

[80]  J. Nesland,et al.  c-erbB-2 expression in primary gastric carcinomas and their metastases. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[81]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Y. Minamisono,et al.  Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinoma , 1992, Journal of surgical oncology.

[83]  T. Kosaka,et al.  The expression of proliferative‐associated nuclear antigen p105 in gastric carcinoma , 1991, Cancer.

[84]  W. Gullick,et al.  c‐erbB‐2 oncoprotein expression in primary human tumors , 1990, Cancer.

[85]  T. Nakajima,et al.  [Prognostic factors in gastric cancer]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

[86]  G. Clark,et al.  Amplification of c-erbB-2 and aggressive human breast tumors? , 1988, Science.

[87]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[88]  T. Rognum.  [Prognostic factors in colo-rectal cancer]. , 1983, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.